Company | Name | Exchange | Sector | Industry | Market Cap | P/E Ratio | PEG Ratio | Last Trade Price | Day Change (%) | Fair Value | Fair Value Upside | Fair Value Label | Analyst Price Target | Analyst Target Upside | Overall Health |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Regeneron Pharma | Vienna | Healthcare | Biotechnology & Medical Research | €54.59B | 14.1x | 1.33 | €497.60 | 1.5% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | ||
argenx SE | Vienna | Healthcare | Biotechnology & Medical Research | €31.93B | 43x | 0.13 | €521.40 | 0% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | ||
IQVIA Holdings | Vienna | Healthcare | Biotechnology & Medical Research | €22.05B | 18.9x | 6.72 | €128.35 | 0% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | ||
BioNTech SE DRC | Vienna | Healthcare | Biotechnology & Medical Research | €21.96B | -32.7x | 0.18 | €85.35 | 0% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | ||
Genmab AS | Vienna | Healthcare | Biotechnology & Medical Research | €10.91B | 10.6x | 0.12 | €173.90 | 0% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | ||
Eurofins Scientific SE | Vienna | Healthcare | Biotechnology & Medical Research | €9.50B | 33.3x | 0.62 | €49.70 | 0% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | ||
Moderna | Vienna | Healthcare | Biotechnology & Medical Research | €8.63B | -2.7x | -0.11 | €21.78 | -0.7% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | ||
Qiagen | Vienna | Healthcare | Biotechnology & Medical Research | €7.95B | 108.4x | -1.39 | €35.93 | 0% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | ||
Galapagos NV | Vienna | Healthcare | Biotechnology & Medical Research | €1.44B | -1,100x | 17.26 | €21.76 | 0.3% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | ||
Evotec | Vienna | Healthcare | Biotechnology & Medical Research | €1.21B | -6.1x | 0.04 | €6.82 | 9.3% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | ||
Novavax | Vienna | Healthcare | Biotechnology & Medical Research | €843.62M | -5x | -0.07 | €5.20 | 0% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | ||
CureVac NV | Vienna | Healthcare | Biotechnology & Medical Research | €628.78M | 3.8x | 0.02 | €2.73 | 0% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | ||
Valneva | Vienna | Healthcare | Biotechnology & Medical Research | €525.51M | -39x | -0.47 | €3.13 | 4.4% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | ||
Medigene | Vienna | Healthcare | Biotechnology & Medical Research | €2.28M | -0.1x | -0 | €0.19 | 0% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ |